Amgen (AMGN) announced that it has filed a Biologics License Application (BLA) with the FDA seeking approval of romosozumab for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that has anti-anabolic effects on bone formation. It has a dual effect of increasing bone formation and decreasing bone breakdown.